Zhitong Finance App News, Hengrui Pharmaceutical (600276.SH) issued an announcement. Recently, the company's subsidiary, Beijing Shengdi Pharmaceutical Co., Ltd. received approval from the State Drug Administration to issue a “Pharmaceutical Clinical Trial Approval Notice” on HRS-8829 injectable concentrated solution and will conduct clinical trials in the near future.

HRS-8829 is a small molecule drug intended for the treatment of acute ischemic stroke. Preclinical studies have shown that HRS-8829 can significantly reduce neurological function scores, reduce cerebral infarction and cerebral edema, inhibit the expression of inflammatory factors, reduce the number of brain neurons, and inhibit brain apoptosis. Phase I clinical trials of the single drug are underway. HRS-8829 is expected to provide a new treatment for patients with acute ischemic stroke when used in combination with the small molecule antioxidant edaravone. Up to now, HRS-8829 concentrated solution for injection has invested about 16.6 million yuan in R&D (unaudited).

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.